CN105209456B - 表皮生长因子受体的活化突变形式的喹唑啉抑制剂 - Google Patents

表皮生长因子受体的活化突变形式的喹唑啉抑制剂 Download PDF

Info

Publication number
CN105209456B
CN105209456B CN201480012092.3A CN201480012092A CN105209456B CN 105209456 B CN105209456 B CN 105209456B CN 201480012092 A CN201480012092 A CN 201480012092A CN 105209456 B CN105209456 B CN 105209456B
Authority
CN
China
Prior art keywords
pharmaceutically acceptable
compound
acceptable salt
formula
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480012092.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN105209456A (zh
Inventor
D.Y.李
王家宾
杨振帆
曾庆北
张小林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50288181&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN105209456(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Priority to CN201480012092.3A priority Critical patent/CN105209456B/zh
Publication of CN105209456A publication Critical patent/CN105209456A/zh
Application granted granted Critical
Publication of CN105209456B publication Critical patent/CN105209456B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201480012092.3A 2013-03-06 2014-03-05 表皮生长因子受体的活化突变形式的喹唑啉抑制剂 Active CN105209456B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201480012092.3A CN105209456B (zh) 2013-03-06 2014-03-05 表皮生长因子受体的活化突变形式的喹唑啉抑制剂

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN2013072250 2013-03-06
CNPCT/CN2013/072250 2013-03-06
PCT/GB2014/050655 WO2014135876A1 (en) 2013-03-06 2014-03-05 Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor
CN201480012092.3A CN105209456B (zh) 2013-03-06 2014-03-05 表皮生长因子受体的活化突变形式的喹唑啉抑制剂

Publications (2)

Publication Number Publication Date
CN105209456A CN105209456A (zh) 2015-12-30
CN105209456B true CN105209456B (zh) 2018-05-08

Family

ID=50288181

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480012092.3A Active CN105209456B (zh) 2013-03-06 2014-03-05 表皮生长因子受体的活化突变形式的喹唑啉抑制剂

Country Status (42)

Country Link
US (4) US9066979B2 (enExample)
EP (2) EP3342770B1 (enExample)
JP (1) JP5894714B1 (enExample)
KR (1) KR101645112B1 (enExample)
CN (1) CN105209456B (enExample)
AP (1) AP2015008696A0 (enExample)
AR (1) AR095039A1 (enExample)
AU (1) AU2014224382B2 (enExample)
BR (1) BR112015020787B1 (enExample)
CA (1) CA2901269C (enExample)
CL (1) CL2015002361A1 (enExample)
CR (1) CR20150450A (enExample)
CY (1) CY1119487T1 (enExample)
DK (1) DK2964638T3 (enExample)
DO (1) DOP2015000189A (enExample)
ES (1) ES2642201T3 (enExample)
GT (1) GT201500251A (enExample)
HR (1) HRP20171689T1 (enExample)
HU (1) HUE034568T2 (enExample)
IL (1) IL240578B (enExample)
LT (1) LT2964638T (enExample)
MA (1) MA38380A1 (enExample)
ME (1) ME03041B (enExample)
MX (1) MX362247B (enExample)
MY (1) MY186126A (enExample)
NI (1) NI201500123A (enExample)
NO (1) NO2964638T3 (enExample)
PE (1) PE20152000A1 (enExample)
PH (1) PH12015501965B1 (enExample)
PL (1) PL2964638T3 (enExample)
PT (1) PT2964638T (enExample)
RS (1) RS56566B1 (enExample)
RU (1) RU2656597C2 (enExample)
SG (1) SG11201506487YA (enExample)
SI (1) SI2964638T1 (enExample)
SM (1) SMT201700542T1 (enExample)
TN (1) TN2015000368A1 (enExample)
TW (1) TWI543977B (enExample)
UA (1) UA115686C2 (enExample)
UY (1) UY35369A (enExample)
WO (1) WO2014135876A1 (enExample)
ZA (1) ZA201507353B (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3342770B1 (en) * 2013-03-06 2022-03-30 AstraZeneca AB Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor
AU2014308616B2 (en) 2013-08-23 2018-12-06 Neupharma, Inc. Certain chemical entities, compositions, and methods
WO2016051380A1 (en) * 2014-10-01 2016-04-07 Sun Pharmaceutical Industries Limited Crystalline form of afatinib dimaleate
US10947201B2 (en) 2015-02-17 2021-03-16 Neupharma, Inc. Certain chemical entities, compositions, and methods
CN105859641B (zh) 2015-05-05 2018-11-16 杭州华东医药集团新药研究院有限公司 喹唑啉巴豆基化合物二马来酸盐的晶体及其制备方法和用途
CN105503906B (zh) * 2015-12-09 2018-09-11 上海宣创生物科技有限公司 一种三唑并吡嗪衍生物a晶型及其制备方法
CN105503905B (zh) * 2015-12-09 2018-09-11 上海宣创生物科技有限公司 一种三唑并吡嗪衍生物b晶型及其制备方法
EP4006035B1 (en) 2016-08-15 2023-11-22 Neupharma, Inc. Quinazoline derivatives as tyrosine kinase inhibitors for the treatment of cancer
CN108658946B (zh) * 2017-03-28 2020-06-16 焦玉奇 新颖的喹唑啉抑制剂
CN107400094B (zh) * 2017-09-08 2020-04-03 贾玉庆 喹唑啉基羧酸酯类化合物及其用途
CN109721552B (zh) * 2017-10-30 2022-09-20 上海北卡医药技术有限公司 一种吉非替尼的制备方法
CN109721551B (zh) * 2017-10-30 2022-09-20 上海北卡医药技术有限公司 一种3,4-二氢-7-甲氧基-4-氧代喹唑啉-6-醇乙酸酯的制备方法
US11465975B2 (en) 2018-02-08 2022-10-11 Neupharma, Inc Certain chemical entities, compositions, and methods
CN109438423A (zh) * 2018-09-12 2019-03-08 通化师范学院 一种肺癌靶向化合物azd-3759的合成工艺的新方法
KR102802129B1 (ko) * 2018-09-14 2025-05-02 한미약품 주식회사 퀴나졸린 화합물 및 이의 염산염의 결정 형태
CN110903283B (zh) * 2018-09-17 2021-01-01 南京雷正医药科技有限公司 一种取代的喹唑啉类化合物、包含该化合物的药物组合物和该化合物的用途
WO2020057403A1 (zh) * 2018-09-18 2020-03-26 北京越之康泰生物医药科技有限公司 吲哚衍生物及其在医药上的应用
WO2020156564A1 (zh) 2019-02-02 2020-08-06 南京明德新药研发有限公司 作为pd-l1免疫调节剂的乙烯基吡啶甲酰胺基化合物
MX2021011810A (es) 2019-03-29 2021-10-26 Astrazeneca Ab Osimertinib para su uso en el tratamiento de cancer de pulmon de celulas no peque?as.
CN111747931A (zh) * 2019-03-29 2020-10-09 深圳福沃药业有限公司 用于治疗癌症的氮杂芳环酰胺衍生物
BR112021025445B1 (pt) 2019-06-21 2024-02-27 F. Hoffmann-La Roche Ag Composto, composição farmacêutica e usos de um composto
CN110590683B (zh) * 2019-10-11 2022-08-19 山东四环药业股份有限公司 一种靶向药物azd3759中间体的制备方法
US20210161897A1 (en) 2019-11-12 2021-06-03 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
AU2021211871A1 (en) 2020-01-20 2022-09-08 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
US20210369709A1 (en) 2020-05-27 2021-12-02 Astrazeneca Ab EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER
CN111675700A (zh) * 2020-06-22 2020-09-18 通化师范学院 一种抗癌新药azd3759的制备方法
CN111662273A (zh) * 2020-06-22 2020-09-15 通化师范学院 一种酪氨酸激酶抑制剂azd3759的制备方法
CN111848584A (zh) * 2020-07-10 2020-10-30 江南大学 一种多取代喹唑啉类化合物及其应用
CN113943273A (zh) * 2020-07-17 2022-01-18 上海天慈国际药业有限公司 一种肺癌药物azd3759的制备方法
CN113135901A (zh) * 2021-04-12 2021-07-20 南京雷正医药科技有限公司 氘代的喹唑啉类盐酸盐化合物的晶型及其制备和应用
IL315848A (en) 2022-03-31 2024-11-01 Astrazeneca Ab Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in combination with an AKT inhibitor for cancer treatment
WO2023209090A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds and their application in the treatment of cancer
CA3249080A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Condensed bicyclic heteroaromatic compounds and their use in the treatment of cancer
WO2023209088A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds and their use in the treatment of cancer
US20240116926A1 (en) 2022-04-28 2024-04-11 Astrazeneca Ab Heteroaromatic compounds
KR20250029133A (ko) 2022-06-27 2025-03-04 아스트라제네카 아베 암 치료를 위한 표피성장인자 수용체 티로신 키나제 억제제를 포함하는 조합물
CN115813927A (zh) * 2022-07-06 2023-03-21 江苏晨泰医药科技有限公司 受体酪氨酸激酶抑制剂与联苯环辛二稀木脂素的联合用药及其用途
CN119654152A (zh) 2022-07-08 2025-03-18 阿斯利康(瑞典)有限公司 与hgf-受体抑制剂组合用于治疗癌症的表皮生长因子受体酪氨酸激酶抑制剂
EP4651875A2 (en) * 2023-02-21 2025-11-26 Prosetta Biosciences, Inc. Quinazoline compounds and uses
CN118063441B (zh) * 2024-02-03 2025-09-19 四川大学华西医院 一种氨基喹唑啉类化合物的制备及抗肿瘤作用
CN119192146B (zh) * 2024-08-16 2025-08-29 安徽法尔麦斯生物科技有限公司 一种抑制剂化合物及应用和治疗癌症的药物
CN119912429B (zh) * 2025-01-21 2025-11-04 安徽医科大学 一类具有抗炎活性的喹唑啉类化合物或其药学上可接受的盐、药物组合物及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080167328A1 (en) * 2005-05-12 2008-07-10 Wenlin Huang Quinazoline derivatives
US20080177068A1 (en) * 2005-05-12 2008-07-24 Wenlin Huang Quinazole derivatives
CN101356171A (zh) * 2005-11-15 2009-01-28 阿雷生物药品公司 作为erbbi型受体酪氨酸激酶抑制剂用于治疗增殖性疾病的n4-苯基-喹唑啉-4-胺衍生物和相关化合物

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
US5821332A (en) 1993-11-03 1998-10-13 The Board Of Trustees Of The Leland Stanford Junior University Receptor on the surface of activated CD4+ T-cells: ACT-4
US6242566B1 (en) 1994-02-10 2001-06-05 Board Of Trustees Of The Leland Stanford Junior University Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
GB9607729D0 (en) 1996-04-13 1996-06-19 Zeneca Ltd Quinazoline derivatives
AU2873999A (en) 1998-02-24 1999-09-06 Sisters Of Providence In Oregon Compositions containing an OX-40 receptor binding agent or nucleic acid encoding the same and methods for enhancing antigen-specific immune response
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
DE19911509A1 (de) 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
HK1046688A1 (zh) 1999-09-21 2003-01-24 Astrazeneca Ab 喹唑啉化合物和含有喹唑啉化合物的藥物組合物
US6656946B2 (en) 2000-08-26 2003-12-02 Boehringer Ingelheim Pharma Kg Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
DE10042058A1 (de) 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
TWI324597B (en) 2002-03-28 2010-05-11 Astrazeneca Ab Quinazoline derivatives
AU2003226705B2 (en) * 2002-03-30 2008-11-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg 4-(N-phenylamino)-quinazolines / quinolines as tyrosine kinase inhibitors
CA2489004C (en) 2002-06-13 2013-01-08 Crucell Holland B.V. Agonistic binding molecules to the human ox40 receptor
CN101899114A (zh) 2002-12-23 2010-12-01 惠氏公司 抗pd-1抗体及其用途
BRPI0413066A (pt) 2003-07-29 2006-10-17 Astrazeneca Ab derivado de quinazolina, ou um sal farmaceuticamente aceitável, ou um éster farmaceuticamente aceitável do mesmo, da fórmula i, uso e processo para a preparação do mesmo, composto, composição farmacêutica, e, métodos para a produção de um efeito antiproliferativo em um animal de sangue quente, para a prevenção ou tratamento de um tumor, para prover um efeito inibitório de tirosina quinase de egfr seletivo, e para tratar um cáncer em um animal de sangue quente
EP1664030A1 (en) 2003-09-16 2006-06-07 AstraZeneca AB Quinazoline derivatives
DE602004004811T2 (de) 2003-09-19 2007-11-22 Astrazeneca Ab Chinazolinderivate
JP4036885B2 (ja) 2003-09-19 2008-01-23 アストラゼネカ アクチボラグ キナゾリン誘導体
WO2005097137A2 (en) 2004-03-31 2005-10-20 The Scripps Research Institute Advanced quinazoline based protein kinase inhibitors
EP2439285B1 (en) 2004-03-31 2019-05-08 The General Hospital Corporation Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments
CN109485727A (zh) 2005-05-09 2019-03-19 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
KR101411165B1 (ko) 2005-07-01 2014-06-25 메다렉스, 엘.엘.시. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날항체
US20100234371A1 (en) 2005-08-22 2010-09-16 Frank Himmelsbach Bicyclic heterocycles, pharmaceutical compositions containing these compounds, the use thereof and processes for the preparation thereof
TWI405756B (zh) 2005-12-21 2013-08-21 Array Biopharma Inc 新穎硫酸氫鹽
BRPI0602275A (pt) 2006-03-24 2007-11-27 Astrazeneca Ab derivado de quinazolina, composição farmacêutica, uso de um derivado de quinazolina, métodos para produzir um efeito anti-proliferativo em um animal de sangue quente e para tratar um cáncer em um animal de sangue quente e processo para a preparação de um derivado de quinalizona
PL2242773T3 (pl) 2008-02-11 2017-11-30 Cure Tech Ltd. Przeciwciała monoklonalne do leczenia nowotworu
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
CN101367793B (zh) 2008-09-26 2013-09-11 中国科学院广州生物医药与健康研究院 一种具有抗肿瘤活性的氨基喹唑啉衍生物及其盐类
WO2010061208A2 (en) 2008-11-03 2010-06-03 Astrazeneca Ab Therapeutic treatment 555
WO2010077634A1 (en) 2008-12-09 2010-07-08 Genentech, Inc. Anti-pd-l1 antibodies and their use to enhance t-cell function
US9050341B2 (en) 2009-07-14 2015-06-09 Natco Pharma Limited Methods of treating drug resistant and other tumors by administering 6,7-dialkoxy quinazoline derivatives
NZ599405A (en) 2009-11-24 2014-09-26 Medimmune Ltd Targeted binding agents against b7-h1
EP2719699B1 (en) 2009-12-31 2015-07-08 Hutchison Medipharma Limited Certain triazolopyrazines, compositions thereof and methods of use therefor
CN101857618B (zh) 2010-06-13 2015-11-25 中国海洋大学 作为蛋白酪氨酸激酶抑制剂的一系列喹唑啉糖衍生物，其制备方法和应用
EA029793B1 (ru) 2010-08-23 2018-05-31 Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем Антитела к ох40 и способы их применения
PL2699264T3 (pl) 2011-04-20 2018-08-31 Medimmune, Llc Przeciwciała i inne cząsteczki wiążące B7-H1 i PD-1
CN104736168B (zh) 2012-05-31 2018-09-21 索伦托治疗有限公司 与pd-l1结合的抗原结合蛋白
EP3342770B1 (en) * 2013-03-06 2022-03-30 AstraZeneca AB Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080167328A1 (en) * 2005-05-12 2008-07-10 Wenlin Huang Quinazoline derivatives
US20080177068A1 (en) * 2005-05-12 2008-07-24 Wenlin Huang Quinazole derivatives
CN101356171A (zh) * 2005-11-15 2009-01-28 阿雷生物药品公司 作为erbbi型受体酪氨酸激酶抑制剂用于治疗增殖性疾病的n4-苯基-喹唑啉-4-胺衍生物和相关化合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Novel EGFR inhibitors prepared by combination of dithiocarbamic acid esters and 4-anilinoquinazolines;Ri-Dong Li, et al.;《Bioorganic & Medicinal Chemistry Letters》;20110428;第21卷;第3637-3640页 *

Also Published As

Publication number Publication date
SI2964638T1 (sl) 2017-11-30
CN105209456A (zh) 2015-12-30
HK1216315A1 (en) 2016-11-04
AU2014224382A1 (en) 2015-09-03
EP3342770A1 (en) 2018-07-04
CA2901269A1 (en) 2014-09-12
CL2015002361A1 (es) 2016-01-04
JP5894714B1 (ja) 2016-03-30
UA115686C2 (uk) 2017-12-11
NZ710850A (en) 2020-09-25
US9718806B2 (en) 2017-08-01
TW201520206A (zh) 2015-06-01
TWI543977B (zh) 2016-08-01
PE20152000A1 (es) 2016-01-22
KR101645112B1 (ko) 2016-08-02
NI201500123A (es) 2016-02-16
WO2014135876A1 (en) 2014-09-12
MX362247B (es) 2019-01-09
ZA201507353B (en) 2017-03-29
GT201500251A (es) 2017-10-09
UY35369A (es) 2014-08-29
HUE034568T2 (en) 2018-02-28
DOP2015000189A (es) 2015-08-31
EP2964638A1 (en) 2016-01-13
PT2964638T (pt) 2017-11-14
MX2015011818A (es) 2016-01-08
BR112015020787A2 (pt) 2017-07-18
AR095039A1 (es) 2015-09-16
US9066979B2 (en) 2015-06-30
RS56566B1 (sr) 2018-02-28
US20180016259A1 (en) 2018-01-18
HRP20171689T1 (hr) 2018-02-23
ME03041B (me) 2018-10-20
US9375432B2 (en) 2016-06-28
AP2015008696A0 (en) 2015-08-31
PH12015501965B1 (en) 2021-08-04
PL2964638T3 (pl) 2018-01-31
US20160340342A1 (en) 2016-11-24
DK2964638T3 (en) 2017-10-30
CA2901269C (en) 2022-01-18
CY1119487T1 (el) 2018-03-07
IL240578A0 (en) 2015-09-24
RU2656597C2 (ru) 2018-06-06
LT2964638T (lt) 2017-12-27
KR20150083782A (ko) 2015-07-20
EP3342770B1 (en) 2022-03-30
SG11201506487YA (en) 2015-09-29
JP2016511225A (ja) 2016-04-14
EP2964638B1 (en) 2017-08-09
PH12015501965A1 (en) 2016-01-11
RU2015139513A (ru) 2017-04-10
IL240578B (en) 2019-03-31
BR112015020787B1 (pt) 2022-12-06
NO2964638T3 (enExample) 2018-01-06
TN2015000368A1 (en) 2017-01-03
CR20150450A (es) 2015-12-01
US20150320751A1 (en) 2015-11-12
US20140255428A1 (en) 2014-09-11
MY186126A (en) 2021-06-24
MA38380A1 (fr) 2017-01-31
SMT201700542T1 (it) 2018-01-11
ES2642201T3 (es) 2017-11-15
AU2014224382B2 (en) 2016-11-10

Similar Documents

Publication Publication Date Title
CN105209456B (zh) 表皮生长因子受体的活化突变形式的喹唑啉抑制剂
JP7540953B2 (ja) Ｅｒｂｂ受容体阻害剤
AU2016323399B2 (en) 8-(6-(3-(amino)propoxy)-3-pyridyl)-1 -isopropyl-imidazo(4,5-c)quinolin-2-one derivatives as selective modulators of ataxia telangiectasia mutated (ATM) kinase for the treatment of cancer
CN113307797B (zh) 一种多取代喹唑啉类化合物及其应用
JP2020517677A (ja) Ｃ５−アニリノキナゾリン化合物及び癌の処置におけるそれらの使用
TW201808948A (zh) 咪唑并[4,5-c]喹啉-2-酮化合物以及它們在治療癌症中之用途
CN110903283B (zh) 一种取代的喹唑啉类化合物、包含该化合物的药物组合物和该化合物的用途
EA038233B1 (ru) ДЕЙТЕРИРОВАННЫЕ СОЕДИНЕНИЯ ИМИДАЗО[4,5-c]ХИНОЛИН-2-ОНА И ИХ ПРИМЕНЕНИЕ В ЛЕЧЕНИИ РАКА
ES2887261T3 (es) Compuestos de fenoxiquinazolina y su uso para tratar el cáncer
JP6586463B2 (ja) ＰＩ３Ｋβ阻害剤としての複素環連結イミダゾピリダジン誘導体
HK1216315B (en) Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor
US20220259195A1 (en) Crystalline forms of a cyclin-dependent kinase inhibitor
NZ710850B2 (en) Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor
WO2021020586A1 (ja) 複素環化合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant